Plus, news about Caliway Biopharmaceuticals, Orca Bio, Alterity Therapeutics and Ascentage Pharma:
Roivant discontinues rare lung disease drug: The termination, disclosed in Roivant’s fourth-quarter results, follows a Phase 2
↧
